Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Lung Cancer

  Free Subscription


Articles published in Lung Cancer

Retrieve available abstracts of 348 articles:
HTML format
Text format



Single Articles


    April 2017
  1. HOLBRECHTS S, Gorham J, Sideris S, Meert AP, et al
    Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 2: Hematologic, cutaneous and vascular syndromes.
    Lung Cancer. 2017;106:93-101.
    PubMed     Text format     Abstract available


  2. BENTEA G, Sculier C, Grigoriu B, Meert AP, et al
    Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 3: Neurological paraneoplastic syndromes, involving the central nervous system.
    Lung Cancer. 2017;106:83-92.
    PubMed     Text format     Abstract available


  3. FUJIWARA A, Shintani Y, Funaki S, Kawamura T, et al
    Pirfenidone plays a biphasic role in inhibition of epithelial-mesenchymal transition in non-small cell lung cancer.
    Lung Cancer. 2017;106:8-16.
    PubMed     Text format     Abstract available


  4. KIM DW, Garon EB, Jatoi A, Keefe DM, et al
    Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042).
    Lung Cancer. 2017;106:76-82.
    PubMed     Text format     Abstract available


  5. REMON J, Pardo N, Martinez-Marti A, Cedres S, et al
    Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches.
    Lung Cancer. 2017;106:70-75.
    PubMed     Text format     Abstract available


  6. MADDISON P
    Effects of aspirin on small-cell lung cancer mortality and metastatic presentation.
    Lung Cancer. 2017;106:67-69.
    PubMed     Text format     Abstract available


  7. SIMMONS VN, Gray JE, Schabath MB, Wilson LE, et al
    High-risk community and primary care providers knowledge about and barriers to low-dose computed topography lung cancer screening.
    Lung Cancer. 2017;106:42-49.
    PubMed     Text format     Abstract available


  8. LIU M, Wampfler JA, Dai J, Gupta R, et al
    Chest wall resection for non-small cell lung cancer: A case-matched study of postoperative pulmonary function and quality of life.
    Lung Cancer. 2017;106:37-41.
    PubMed     Text format     Abstract available


  9. HALPENNY DF, McEvoy S, Li A, Hayan S, et al
    Renal cyst formation in patients treated with crizotinib for non-small cell lung cancer-Incidence, radiological features and clinical characteristics.
    Lung Cancer. 2017;106:33-36.
    PubMed     Text format     Abstract available


  10. IRIKI T, Ohnishi K, Fujiwara Y, Horlad H, et al
    The cell-cell interaction between tumor-associated macrophages and small cell lung cancer cells is involved in tumor progression via STAT3 activation.
    Lung Cancer. 2017;106:22-32.
    PubMed     Text format     Abstract available


  11. KASAHARA N, Kenmotsu H, Serizawa M, Umehara R, et al
    Plasma epidermal growth factor receptor mutation testing with a chip-based digital PCR system in patients with advanced non-small cell lung cancer.
    Lung Cancer. 2017;106:138-144.
    PubMed     Text format     Abstract available


  12. JONES BS, Jerome MS, Miley D, Jackson BE, et al
    Pilot phase II study of metronomic chemotherapy in combination with bevacizumab in patients with advanced non-squamous non-small cell lung cancer.
    Lung Cancer. 2017;106:125-130.
    PubMed     Text format     Abstract available


  13. OU SI, Lee TK, Young L, Fernandez-Rocha MY, et al
    Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?
    Lung Cancer. 2017;106:110-114.
    PubMed     Text format     Abstract available


  14. DURIEUX V, Coureau M, Meert AP, Berghmans T, et al
    Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature.
    Lung Cancer. 2017;106:102-109.
    PubMed     Text format     Abstract available


  15. BAGLEY SJ, Kothari S, Aggarwal C, Bauml JM, et al
    Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.
    Lung Cancer. 2017;106:1-7.
    PubMed     Text format     Abstract available


    March 2017
  16. CAPELLETTO E, Mariniello A, Novello S
    Targeted therapy in small cell lung cancer: A new era?
    Lung Cancer. 2017 Mar 12. pii: S0169-5002(17)30258.
    PubMed     Text format    


  17. SALGIA R, Stille JR, Weaver RW, McCleod M, et al
    A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer.
    Lung Cancer. 2017;105:7-13.
    PubMed     Text format     Abstract available


  18. VERONESI G, Colombo P, Novellis P, Crepaldi A, et al
    Pilot study on use of home telephoning to identify and recruit high-risk individuals for lung cancer screening.
    Lung Cancer. 2017;105:39-41.
    PubMed     Text format     Abstract available


  19. GACHECHILADZE M, Skarda J, Kolek V, Grygarkova I, et al
    Prognostic and predictive value of loss of nuclear RAD51 immunoreactivity in resected non-small cell lung cancer patients.
    Lung Cancer. 2017;105:31-38.
    PubMed     Text format     Abstract available


  20. KATAKAMI N, Hida T, Nokihara H, Imamura F, et al
    Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer.
    Lung Cancer. 2017;105:23-30.
    PubMed     Text format     Abstract available


  21. SOO RA, Kim HR, Asuncion BR, Fazreen Z, et al
    Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer.
    Lung Cancer. 2017;105:17-22.
    PubMed     Text format     Abstract available


  22. YONESAKA K, Hirotani K, von Pawel J, Dediu M, et al
    Circulating heregulin level is associated with the efficacy of patritumab combined with erlotinib in patients with non-small cell lung cancer.
    Lung Cancer. 2017;105:1-6.
    PubMed     Text format     Abstract available


    February 2017
  23. TAYLOR KL, Hagerman CJ, Luta G, Bellini PG, et al
    Preliminary evaluation of a telephone-based smoking cessation intervention in the lung cancer screening setting: A randomized clinical trial.
    Lung Cancer. 2017 Feb 14. pii: S0169-5002(17)30029.
    PubMed     Text format     Abstract available


  24. SU XD, Xie HJ, Liu QW, Mo YX, et al
    The prognostic impact of tumor volume on stage I non-small cell lung cancer.
    Lung Cancer. 2017;104:91-97.
    PubMed     Text format     Abstract available


  25. SESUMI Y, Suda K, Mizuuchi H, Kobayashi Y, et al
    Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells.
    Lung Cancer. 2017;104:85-90.
    PubMed     Text format     Abstract available


  26. KAWAGUCHI K, Yokoi K, Niwa H, Ohde Y, et al
    A prospective, multi-institutional phase II study of induction chemoradiotherapy followed by surgery in patients with non-small cell lung cancer involving the chest wall (CJLSG0801).
    Lung Cancer. 2017;104:79-84.
    PubMed     Text format     Abstract available


  27. AWAN S, Crosby V, Potter V, Hennig I, et al
    Is clarithromycin a potential treatment for cachexia in people with lung cancer? A feasibility study.
    Lung Cancer. 2017;104:75-78.
    PubMed     Text format     Abstract available


  28. CHANG GC, Tseng CH, Hsu KH, Yu CJ, et al
    Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.
    Lung Cancer. 2017;104:58-64.
    PubMed     Text format     Abstract available


  29. LAM VK, Bentzen SM, Mohindra P, Nichols EM, et al
    Obesity is associated with long-term improved survival in definitively treated locally advanced non-small cell lung cancer (NSCLC).
    Lung Cancer. 2017;104:52-57.
    PubMed     Text format     Abstract available


  30. PAZ-ARES LG, Zimmermann A, Ciuleanu T, Bunn PA, et al
    Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer.
    Lung Cancer. 2017;104:45-51.
    PubMed     Text format     Abstract available


  31. LILLIE SE, Fu SS, Fabbrini AE, Rice KL, et al
    What factors do patients consider most important in making lung cancer screening decisions? Findings from a demonstration project conducted in the Veterans Health Administration.
    Lung Cancer. 2017;104:38-44.
    PubMed     Text format     Abstract available


  32. KOH YW, Lee SJ, Park SY
    Differential expression and prognostic significance of GLUT1 according to histologic type of non-small-cell lung cancer and its association with volume-dependent parameters.
    Lung Cancer. 2017;104:31-37.
    PubMed     Text format     Abstract available


  33. MESSARITAKIS I, Politaki E, Plataki M, Karavassilis V, et al
    Heterogeneity of circulating tumor cells (CTCs) in patients with recurrent small cell lung cancer (SCLC) treated with pazopanib.
    Lung Cancer. 2017;104:16-23.
    PubMed     Text format     Abstract available


  34. AWAD MM, Chu QS, Gandhi L, Stephenson JJ, et al
    An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC).
    Lung Cancer. 2017;104:126-130.
    PubMed     Text format     Abstract available


  35. KATO T, Masuda N, Nakanishi Y, Takahashi M, et al
    Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer.
    Lung Cancer. 2017;104:111-118.
    PubMed     Text format     Abstract available


  36. SHIN B, Shin S, Chung MJ, Lee H, et al
    Different histological subtypes of peripheral lung cancer based on emphysema distribution in patients with both airflow limitation and CT-determined emphysema.
    Lung Cancer. 2017;104:106-110.
    PubMed     Text format     Abstract available


  37. OKUMA Y, Hosomi Y, Nakahara Y, Watanabe K, et al
    High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer.
    Lung Cancer. 2017;104:1-6.
    PubMed     Text format     Abstract available


    January 2017
  38. SLOTMAN B
    What is the optimal radiotherapy schedule for limited stage small cell lung cancer?
    Lung Cancer. 2017 Jan 4. pii: S0169-5002(17)30002.
    PubMed     Text format     Abstract available


  39. GOW CH, Hsieh MS, Wu SG, Shih JY, et al
    A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population.
    Lung Cancer. 2017;103:82-89.
    PubMed     Text format     Abstract available


  40. THOMAS DC, Arnold BN, Rosen JE, Salazar MC, et al
    Defining outcomes of patients with clinical stage I small cell lung cancer upstaged at surgery.
    Lung Cancer. 2017;103:75-81.
    PubMed     Text format     Abstract available


  41. KANISKI F, Enewold L, Thomas A, Malik S, et al
    Temporal patterns of care and outcomes of non-small cell lung cancer patients in the United States diagnosed in 1996, 2005, and 2010.
    Lung Cancer. 2017;103:66-74.
    PubMed     Text format     Abstract available


  42. SAMSON P, Keogan K, Crabtree T, Colditz G, et al
    Interpreting survival data from clinical trials of surgery versus stereotactic body radiation therapy in operable Stage I non-small cell lung cancer patients.
    Lung Cancer. 2017;103:6-10.
    PubMed     Text format     Abstract available


  43. MCGOWAN M, Hoven AS, Lund-Iversen M, Solberg S, et al
    PIK3CA mutations as prognostic factor in squamous cell lung carcinoma.
    Lung Cancer. 2017;103:52-57.
    PubMed     Text format     Abstract available


  44. REUNGWETWATTANA T, Liang Y, Zhu V, Ou SI, et al
    The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable.
    Lung Cancer. 2017;103:27-37.
    PubMed     Text format     Abstract available


  45. STAHL JM, Corso CD, Verma V, Park HS, et al
    Trends in stereotactic body radiation therapy for stage I small cell lung cancer.
    Lung Cancer. 2017;103:11-16.
    PubMed     Text format     Abstract available


  46. VON LAFFERT M, Schirmacher P, Warth A, Weichert W, et al
    ALK-Testing in non-small cell lung cancer (NSCLC): Immunohistochemistry (IHC) and/or fluorescence in-situ Hybridisation (FISH)?: Statement of the Germany Society for Pathology (DGP) and the Working Group Thoracic Oncology (AIO) of the German Cancer So
    Lung Cancer. 2017;103:1-5.
    PubMed     Text format     Abstract available


    December 2016
  47. MALIK N, Palma D
    Oligometastatic non-small cell lung cancer: Where do we go next?
    Lung Cancer. 2016 Dec 26. pii: S0169-5002(16)30581.
    PubMed     Text format    


  48. VRANCKEN A, Lepers S, Peeters L, Oyen C, et al
    The challenge of molecular testing for clinical trials in advanced non-small cell lung cancer patients: Analysis of a prospective database.
    Lung Cancer. 2016;102:96-100.
    PubMed     Text format     Abstract available


  49. HALVORSEN TO, Herje M, Levin N, Bremnes RM, et al
    Tumour size reduction after the first chemotherapy-course and outcomes of chemoradiotherapy in limited disease small-cell lung cancer.
    Lung Cancer. 2016;102:9-14.
    PubMed     Text format     Abstract available


  50. LEE SH, Sung JY, Yong D, Chun J, et al
    Characterization of microbiome in bronchoalveolar lavage fluid of patients with lung cancer comparing with benign mass like lesions.
    Lung Cancer. 2016;102:89-95.
    PubMed     Text format     Abstract available


  51. HANNA NH, Kaiser R, Sullivan RN, Aren OR, et al
    Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial.
    Lung Cancer. 2016;102:65-73.
    PubMed     Text format     Abstract available


  52. TOMIZAWA K, Nishino M, Sesumi Y, Kobayashi Y, et al
    Prognostic impact of pleural lavage cytology in patients with primary lung cancer.
    Lung Cancer. 2016;102:60-64.
    PubMed     Text format     Abstract available


  53. GUPTA A, Majumder K, Arora N, Mayo HG, et al
    Premorbid body mass index and mortality in patients with lung cancer: A systematic review and meta-analysis.
    Lung Cancer. 2016;102:49-59.
    PubMed     Text format     Abstract available


  54. TANIZAKI J, Hayashi H, Kimura M, Tanaka K, et al
    Report of two cases of pseudoprogression in patients with non-small cell lung cancer treated with nivolumab-including histological analysis of one case after tumor regression.
    Lung Cancer. 2016;102:44-48.
    PubMed     Text format     Abstract available


  55. LEVACQ D, D'Haene N, de Wind R, Remmelink M, et al
    Histological transformation of ALK rearranged adenocarcinoma into small cell lung cancer: A new mechanism of resistance to ALK inhibitors.
    Lung Cancer. 2016;102:38-41.
    PubMed     Text format     Abstract available


  56. CICENAS S, Geater SL, Petrov P, Hotko Y, et al
    Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study).
    Lung Cancer. 2016;102:30-37.
    PubMed     Text format     Abstract available


  57. LE FOURNIS S, Gohier P, Urban T, Jeanfaivre T, et al
    Corneal graft rejection in a patient treated with nivolumab for primary lung cancer.
    Lung Cancer. 2016;102:28-29.
    PubMed     Text format     Abstract available


  58. FUKUDA S, Oguri T, Kunii E, Sone K, et al
    A folylpoly-gamma-glutamate synthase single nucleotide polymorphism associated with response to pemetrexed treatment combined with platinum for non-small cell lung cancer.
    Lung Cancer. 2016;102:15-20.
    PubMed     Text format     Abstract available


  59. DAI SD, Wang Y, Jiang GY, Zhang PX, et al
    RETRACTED: Kaiso is expressed in lung cancer: Its expression and localization is affected by p120ctn.
    Lung Cancer. 2016;102:141.
    PubMed     Text format    


  60. CHAPMAN AM, Sun KY, Ruestow P, Cowan DM, et al
    Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers.
    Lung Cancer. 2016;102:122-134.
    PubMed     Text format     Abstract available


  61. WONG ML, McMurry TL, Stukenborg GJ, Francescatti AB, et al
    Impact of age and comorbidity on treatment of non-small cell lung cancer recurrence following complete resection: A nationally representative cohort study.
    Lung Cancer. 2016;102:108-117.
    PubMed     Text format     Abstract available


    November 2016
  62. ROLFO C, Giallombardo M, Reclusa P, Sirera R, et al
    Exosomes in lung cancer liquid biopsies: Two sides of the same coin?
    Lung Cancer. 2016 Nov 18. pii: S0169-5002(16)30530.
    PubMed     Text format    


  63. GOFFIN JR, Flanagan WM, Miller AB, Fitzgerald NR, et al
    Biennial lung cancer screening in Canada with smoking cessation-outcomes and cost-effectiveness.
    Lung Cancer. 2016;101:98-103.
    PubMed     Text format     Abstract available


  64. SUZUKI Y, Okamoto T, Fujishita T, Katsura M, et al
    Clinical implications of sarcopenia in patients undergoing complete resection for early non-small cell lung cancer.
    Lung Cancer. 2016;101:92-97.
    PubMed     Text format     Abstract available


  65. OHGAMI M, Kaburagi T, Kurosawa A, Homma M, et al
    Drug interaction between erlotinib and phenytoin for brain metastases in a patient with nonsmall cell lung cancer.
    Lung Cancer. 2016;101:9-10.
    PubMed     Text format     Abstract available


  66. BERNHARDT D, Bozorgmehr F, Adeberg S, Opfermann N, et al
    Outcome in patients with small cell lung cancer re-irradiated for brain metastases after prior prophylactic cranial irradiation.
    Lung Cancer. 2016;101:76-81.
    PubMed     Text format     Abstract available


  67. HENDRIKS LE, Brouns AJ, Amini M, Uyterlinde W, et al
    Development of symptomatic brain metastases after chemoradiotherapy for stage III non-small cell lung cancer: Does the type of chemotherapy regimen matter?
    Lung Cancer. 2016;101:68-75.
    PubMed     Text format     Abstract available


  68. KIM JY, Sun V, Raz DJ, Williams AC, et al
    The impact of lung cancer surgery on quality of life trajectories in patients and family caregivers.
    Lung Cancer. 2016;101:35-39.
    PubMed     Text format     Abstract available


  69. VERONESI G, Novellis P, Voulaz E, Alloisio M, et al
    Robot-assisted surgery for lung cancer: State of the art and perspectives.
    Lung Cancer. 2016;101:28-34.
    PubMed     Text format     Abstract available


  70. THONGPRASERT S, Yang PC, Lee JS, Soo R, et al
    The prevalence of expression of MAGE-A3 and PRAME tumor antigens in East and South East Asian non-small cell lung cancer patients.
    Lung Cancer. 2016;101:137-144.
    PubMed     Text format     Abstract available


  71. NUMAN RC, Berge MT, Burgers JA, Klomp HM, et al
    Peri- and postoperative management of stage I-III Non Small Cell Lung Cancer: Which quality of care indicators are evidence-based?
    Lung Cancer. 2016;101:129-136.
    PubMed     Text format     Abstract available


  72. LAM SK, Leung LL, Li YY, Zheng CY, et al
    Combination effects of arsenic trioxide and fibroblast growth factor receptor inhibitor in squamous cell lung carcinoma.
    Lung Cancer. 2016;101:111-119.
    PubMed     Text format     Abstract available


  73. TANIZAKI J, Banno E, Togashi Y, Hayashi H, et al
    Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation.
    Lung Cancer. 2016;101:11-15.
    PubMed     Text format     Abstract available


  74. NOSAKI K, Satouchi M, Kurata T, Yoshida T, et al
    Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study.
    Lung Cancer. 2016;101:1-8.
    PubMed     Text format     Abstract available


    October 2016
  75. REMON J, Girard N, Mazieres J, Dansin E, et al
    Erratum to "Sunitinib in patients with advanced thymic malignancies: cohort from the French RYTHMIC network" [Lung Cancer, 97 (July 2016), 99-104].
    Lung Cancer. 2016 Oct 6. pii: S0169-5002(16)30483.
    PubMed     Text format    


  76. VANNUCCI F, Gonzalez-Rivas D
    Is VATS lobectomy standard of care for operable non-small cell lung cancer?
    Lung Cancer. 2016;100:114-9.
    PubMed     Text format     Abstract available


  77. BAUML JM, Troxel A, Epperson CN, Cohen RB, et al
    Scan-associated distress in lung cancer: Quantifying the impact of "scanxiety".
    Lung Cancer. 2016;100:110-3.
    PubMed     Text format     Abstract available


  78. SULLIVAN DR, Forsberg CW, Ganzini L, Au DH, et al
    Depression symptom trends and health domains among lung cancer patients in the CanCORS study.
    Lung Cancer. 2016;100:102-9.
    PubMed     Text format     Abstract available


  79. JEPPESEN SS, Hansen NC, Schytte T, Nielsen M, et al
    Comparison of survival of chronic obstructive pulmonary disease patients with or without a localized non-small cell lung cancer.
    Lung Cancer. 2016;100:90-5.
    PubMed     Text format     Abstract available


  80. MITIN T, Jain A, Degnin C, Chen Y, et al
    Current patterns of care for patients with extensive stage small cell lung cancer: Survey of US radiation oncologists on their recommendations regarding thoracic consolidation radiotherapy.
    Lung Cancer. 2016;100:85-9.
    PubMed     Text format     Abstract available


  81. SORENSEN SF, Demuth C, Weber B, Sorensen BS, et al
    Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR-mutated non-small cell lung cancer treated with erlotinib.
    Lung Cancer. 2016;100:77-84.
    PubMed     Text format     Abstract available


  82. KLUPCZYNSKA A, Derezinski P, Dyszkiewicz W, Pawlak K, et al
    Evaluation of serum amino acid profiles' utility in non-small cell lung cancer detection in Polish population.
    Lung Cancer. 2016;100:71-6.
    PubMed     Text format     Abstract available


  83. JIANG T, Zhai C, Su C, Ren S, et al
    The diagnostic value of circulating cell free DNA quantification in non-small cell lung cancer: A systematic review with meta-analysis.
    Lung Cancer. 2016;100:63-70.
    PubMed     Text format     Abstract available


  84. GIBELIN C, Couraud S
    Somatic alterations in lung cancer: Do environmental factors matter?
    Lung Cancer. 2016;100:45-52.
    PubMed     Text format     Abstract available


  85. NEUMAIR P, Joos L, Warschkow R, Dutly A, et al
    Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study.
    Lung Cancer. 2016;100:38-44.
    PubMed     Text format     Abstract available


  86. SCAGLIOTTI G, Nishio M, Satouchi M, Valmadre G, et al
    A phase 2 randomized study of TAS-102 versus topotecan or amrubicin in patients requiring second-line chemotherapy for small cell lung cancer refractory or sensitive to frontline platinum-based chemotherapy.
    Lung Cancer. 2016;100:20-3.
    PubMed     Text format     Abstract available


    September 2016
  87. ERB CT, Su KW, Soulos PR, Tanoue LT, et al
    Surveillance Practice Patterns after Curative Intent Therapy for Stage I Non-Small-Cell Lung Cancer in the Medicare Population.
    Lung Cancer. 2016;99:200-7.
    PubMed     Text format     Abstract available


  88. YOH K, Hosomi Y, Kasahara K, Yamada K, et al
    A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy.
    Lung Cancer. 2016;99:186-93.
    PubMed     Text format     Abstract available


  89. DAWE DE, Christiansen D, Swaminath A, Ellis PM, et al
    Chemoradiotherapy versus radiotherapy alone in elderly patients with stage III non-small cell lung cancer: A systematic review and meta-analysis.
    Lung Cancer. 2016;99:180-5.
    PubMed     Text format     Abstract available


  90. DAI L, Tsay JC, Li J, Yie TA, et al
    Autoantibodies against tumor-associated antigens in the early detection of lung cancer.
    Lung Cancer. 2016;99:172-9.
    PubMed     Text format     Abstract available


  91. LIN JJ, Ezer N, Sigel K, Mhango G, et al
    The effect of statins on survival in patients with stage IV lung cancer.
    Lung Cancer. 2016;99:137-42.
    PubMed     Text format     Abstract available


  92. USUI K, Sugawara S, Nishitsuji M, Fujita Y, et al
    A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A.
    Lung Cancer. 2016;99:131-6.
    PubMed     Text format     Abstract available


  93. GAINETDINOV IV, Kapitskaya KY, Rykova EY, Ponomaryova AA, et al
    Hypomethylation of human-specific family of LINE-1 retrotransposons in circulating DNA of lung cancer patients.
    Lung Cancer. 2016;99:127-30.
    PubMed     Text format     Abstract available


  94. TABCHI S, Weng X, Blais N
    Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab.
    Lung Cancer. 2016;99:123-6.
    PubMed     Text format     Abstract available


  95. SAKATA Y, Kawamura K, Shingu N, Ichikado K, et al
    Erlotinib plus bevacizumab as an effective treatment for leptomeningeal metastases from EGFR mutation-positive non-small cell lung cancer.
    Lung Cancer. 2016;99:120-2.
    PubMed     Text format     Abstract available


  96. SMIT EF, Wu YL, Gervais R, Zhou C, et al
    A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS).
    Lung Cancer. 2016;99:94-101.
    PubMed     Text format     Abstract available


  97. SALANDER P, Lilliehorn S
    To carry on as before: A meta-synthesis of qualitative studies in lung cancer.
    Lung Cancer. 2016;99:88-93.
    PubMed     Text format     Abstract available


  98. SHIEN K, Papadimitrakopoulou VA, Wistuba II
    Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer.
    Lung Cancer. 2016;99:79-87.
    PubMed     Text format     Abstract available


  99. SHALLWANI SM, Simmonds MJ, Kasymjanova G, Spahija J, et al
    Quality of life, symptom status and physical performance in patients with advanced non-small cell lung cancer undergoing chemotherapy: an exploratory analysis of secondary data.
    Lung Cancer. 2016;99:69-75.
    PubMed     Text format     Abstract available


  100. KIM HR, Lee GO, Choi KH, Kim DK, et al
    SRSF5: a novel marker for small-cell lung cancer and pleural metastatic cancer.
    Lung Cancer. 2016;99:57-65.
    PubMed     Text format     Abstract available


  101. WIDLAK P, Pietrowska M, Polanska J, Marczyk M, et al
    Serum mass profile signature as a biomarker of early lung cancer.
    Lung Cancer. 2016;99:46-52.
    PubMed     Text format     Abstract available


  102. SAKATA S, Saeki S, Okamoto I, Otsubo K, et al
    Phase II trial of weekly nab-paclitaxel for previously treated advanced non-small cell lung cancer: Kumamoto thoracic oncology study group (KTOSG) trial 1301.
    Lung Cancer. 2016;99:41-5.
    PubMed     Text format     Abstract available


  103. JOHNSON AC, Do P, Richard N, Dubos C, et al
    Identification of I1171N resistance mutation in ALK-positive non-small-cell lung cancer tumor sample and circulating tumor DNA.
    Lung Cancer. 2016;99:38-40.
    PubMed     Text format     Abstract available


  104. CAPPUZZO F, Morabito A, Normanno N, Bidoli P, et al
    Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer.
    Lung Cancer. 2016;99:31-7.
    PubMed     Text format     Abstract available


  105. PIETANZA MC, Litvak AM, Varghese AM, Krug LM, et al
    A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer.
    Lung Cancer. 2016;99:23-30.
    PubMed     Text format     Abstract available


  106. ZENKE Y, Umemura S, Sugiyama E, Kirita K, et al
    Successful treatment with afatinib after grade 3 hepatotoxicity induced by both gefitinib and erlotinib in EGFR mutation-positive non-small cell lung cancer.
    Lung Cancer. 2016;99:1-3.
    PubMed     Text format     Abstract available


    August 2016
  107. LACCETTI AL, Pruitt SL, Xuan L, Halm EA, et al
    Prior cancer does not adversely affect survival in locally advanced lung cancer: A national SEER-medicare analysis.
    Lung Cancer. 2016;98:106-13.
    PubMed     Text format     Abstract available


  108. CHEN YM, Lai CH, Rau KM, Huang CH, et al
    Advanced non-Small cell lung cancer patients at the extremes of age in the era of epidermal growth factor receptor tyrosine kinase inhibitors.
    Lung Cancer. 2016;98:99-105.
    PubMed     Text format     Abstract available


  109. PINEIRO B, Simmons VN, Palmer AM, Correa JB, et al
    Smoking cessation interventions within the context of Low-Dose Computed Tomography lung cancer screening: A systematic review.
    Lung Cancer. 2016;98:91-8.
    PubMed     Text format     Abstract available


  110. MONNET I, Audigier-Valette C, Girard N, Vergnenegre A, et al
    Real-life effectiveness of erlotinib as second-line treatment of stage IIIB/IV squamous non-small cell lung cancer: Results of the PEPiTA observational study.
    Lung Cancer. 2016;98:84-90.
    PubMed     Text format     Abstract available


  111. BOYER MJ, Gu L, Wang X, Kelsey CR, et al
    Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer.
    Lung Cancer. 2016;98:76-8.
    PubMed     Text format     Abstract available


  112. SHIMOJI M, Shimizu S, Sato K, Suda K, et al
    Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1).
    Lung Cancer. 2016;98:69-75.
    PubMed     Text format     Abstract available


  113. LI SY, Li Q, Guan WJ, Huang J, et al
    Effects of para-toluenesulfonamide intratumoral injection on non-small cell lung carcinoma with severe central airway obstruction: A multi-center, non-randomized, single-arm, open-label trial.
    Lung Cancer. 2016;98:43-50.
    PubMed     Text format     Abstract available


  114. ZANETTI KA, Wang Z, Aldrich M, Amos CI, et al
    Genome-wide association study confirms lung cancer susceptibility loci on chromosomes 5p15 and 15q25 in an African-American population.
    Lung Cancer. 2016;98:33-42.
    PubMed     Text format     Abstract available


  115. SHOJI F, Morodomi Y, Akamine T, Takamori S, et al
    Predictive impact for postoperative recurrence using the preoperative prognostic nutritional index in pathological stage I non-small cell lung cancer.
    Lung Cancer. 2016;98:15-21.
    PubMed     Text format     Abstract available


  116. CADRANEL J, Park K, Arrieta O, Pless M, et al
    Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study.
    Lung Cancer. 2016;98:9-14.
    PubMed     Text format     Abstract available


  117. MOK T, Ladrera G, Srimuninnimit V, Sriuranpong V, et al
    Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer.
    Lung Cancer. 2016;98:1-8.
    PubMed     Text format     Abstract available


    July 2016
  118. HIDDINGA BI, Pauwels P, Janssens A, van Meerbeeck JP, et al
    O6-Methylguanine-DNA methyltransferase (MGMT): A drugable target in lung cancer?
    Lung Cancer. 2016 Jul 18. pii: S0169-5002(16)30412.
    PubMed     Text format     Abstract available


  119. PHILIPPOV PP
    Express of concern on 'Antirecoverin autoantibodies in the patient with non-small cell lung cancer but without cancer-associated retinopathy'.
    Lung Cancer. 2016 Jul 13. pii: S0169-5002(16)30399.
    PubMed     Text format    


  120. HU H, Xu Z, Li C, Xu C, et al
    MiR-145 and miR-203 represses TGF-beta-induced epithelial-mesenchymal transition and invasion by inhibiting SMAD3 in non-small cell lung cancer cells.
    Lung Cancer. 2016;97:87-94.
    PubMed     Text format     Abstract available


  121. GARCIA-VELLOSO MJ, Bastarrika G, de-Torres JP, Lozano MD, et al
    Assessment of indeterminate pulmonary nodules detected in lung cancer screening: Diagnostic accuracy of FDG PET/CT.
    Lung Cancer. 2016;97:81-6.
    PubMed     Text format     Abstract available


  122. COSTA G, Thuler LC, Ferreira CG
    Epidemiological changes in the histological subtypes of 35,018 non-small-cell lung cancer cases in Brazil.
    Lung Cancer. 2016;97:66-72.
    PubMed     Text format     Abstract available


  123. YOSHIDA T, Oya Y, Tanaka K, Shimizu J, et al
    Clinical impact of crizotinib on central nervous system progression in ALK-positive non-small lung cancer.
    Lung Cancer. 2016;97:43-7.
    PubMed     Text format     Abstract available


  124. SANCHEZ-SALCEDO P, de-Torres JP, Martinez-Urbistondo D, Gonzalez-Gutierrez J, et al
    The neutrophil to lymphocyte and platelet to lymphocyte ratios as biomarkers for lung cancer development.
    Lung Cancer. 2016;97:28-34.
    PubMed     Text format     Abstract available


  125. BRULE SY, Al-Baimani K, Jonker H, Zhang T, et al
    Palliative systemic therapy for advanced non-small cell lung cancer: Investigating disparities between patients who are treated versus those who are not.
    Lung Cancer. 2016;97:15-21.
    PubMed     Text format     Abstract available


  126. KENNEDY MP, Hall PS, Callister ME
    Factors affecting hospital costs in lung cancer patients in the United Kingdom.
    Lung Cancer. 2016;97:8-14.
    PubMed     Text format     Abstract available


  127. NAKAGAWA K, Asamura H, Tsuta K, Nagai K, et al
    The novel one-step nucleic acid amplification (OSNA) assay for the diagnosis of lymph node metastasis in patients with non-small cell lung cancer (NSCLC): Results of a multicenter prospective study.
    Lung Cancer. 2016;97:1-7.
    PubMed     Text format     Abstract available


    June 2016
  128. ROBLES AI, Harris CC
    Integration of multiple "OMIC" biomarkers: A precision medicine strategy for lung cancer.
    Lung Cancer. 2016 Jun 14. pii: S0169-5002(16)30361.
    PubMed     Text format     Abstract available


  129. ROTHSCHILD SI, Gautschi O, Batliner J, Gugger M, et al
    MicroRNA-106a targets autophagy and enhances sensitivity of lung cancer cells to Src inhibitors.
    Lung Cancer. 2016 Jun 14. pii: S0169-5002(16)30362.
    PubMed     Text format     Abstract available


  130. FINAN KM, Hodge G, Reynolds AM, Hodge S, et al
    Corrigendum to "In vitro susceptibility to the pro-apoptotic effects of TIMP-3 gene delivery translates to greater in vivo efficacy versus gene delivery for TIMPs-1 or -2" [Lung Cancer 53 (3) (September 2006) 273-284].
    Lung Cancer. 2016 Jun 13. pii: S0169-5002(16)30360.
    PubMed     Text format    


  131. LI J, Yu J, Liu A, Wang Y, et al
    Retraction notice to "ss-elemene against human lung cancer via up-regulation of P53 protein expression to promote the release of exosome": LUNG 86/2 (2014) 144-150.
    Lung Cancer. 2016;96:120.
    PubMed     Text format    


  132. WEISS E, Ford JC, Olsen KM, Karki K, et al
    Apparent diffusion coefficient (ADC) change on repeated diffusion-weighted magnetic resonance imaging during radiochemotherapy for non-small cell lung cancer: A pilot study.
    Lung Cancer. 2016;96:113-9.
    PubMed     Text format     Abstract available


  133. HAN JY, Kim HY, Lim KY, Hwangbo B, et al
    A phase II study of nintedanib in patients with relapsed small cell lung cancer.
    Lung Cancer. 2016;96:108-12.
    PubMed     Text format     Abstract available


  134. HSU F, De Caluwe A, Anderson D, Nichol A, et al
    EGFR mutation status on brain metastases from non-small cell lung cancer.
    Lung Cancer. 2016;96:101-7.
    PubMed     Text format     Abstract available


  135. ZHOU L, He J, Xiong W, Liu Y, et al
    Impact of whole brain radiation therapy on CSF penetration ability of Icotinib in EGFR-mutated non-small cell lung cancer patients with brain metastases: Results of phase I dose-escalation study.
    Lung Cancer. 2016;96:93-100.
    PubMed     Text format     Abstract available


  136. XU J, Jin B, Chu T, Dong X, et al
    EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China.
    Lung Cancer. 2016;96:87-92.
    PubMed     Text format     Abstract available


  137. CREQUIT P, Ruppert AM, Rozensztajn N, Gounant V, et al
    EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients.
    Lung Cancer. 2016;96:74-7.
    PubMed     Text format     Abstract available


  138. ENOMOTO Y, Inui N, Kato T, Baba T, et al
    Low forced vital capacity predicts cytotoxic chemotherapy-associated acute exacerbation of interstitial lung disease in patients with lung cancer.
    Lung Cancer. 2016;96:63-7.
    PubMed     Text format     Abstract available


  139. KIM HK, Cho JH, Choi YS, Zo JI, et al
    Outcomes of neoadjuvant concurrent chemoradiotherapy followed by surgery for non-small-cell lung cancer with N2 disease.
    Lung Cancer. 2016;96:56-62.
    PubMed     Text format     Abstract available


  140. LI R, Hermann G, Baldini E, Chen A, et al
    Advanced nodal stage predicts venous thromboembolism in patients with locally advanced non-small cell lung cancer.
    Lung Cancer. 2016;96:41-7.
    PubMed     Text format     Abstract available


  141. KHAKWANI A, Hubbard RB, Beckett P, Borthwick D, et al
    Which patients are assessed by lung cancer nurse specialists? A national lung cancer audit study of over 128,000 patients across england.
    Lung Cancer. 2016;96:33-40.
    PubMed     Text format     Abstract available


  142. PATIL T, Aisner DL, Noonan SA, Bunn PA, et al
    Malignant pleural disease is highly associated with subsequent peritoneal metastasis in patients with stage IV non-small cell lung cancer independent of oncogene status.
    Lung Cancer. 2016;96:27-32.
    PubMed     Text format     Abstract available


  143. SAKURAI S, Shirai T, Akamatsu T, Hayashi I, et al
    Endobronchial lesions as a predictor of impaired cough-related quality of life in lung cancer.
    Lung Cancer. 2016;96:25-6.
    PubMed     Text format    


  144. OLIVEIRA MB, Mello FC, Paschoal ME
    The relationship between lung cancer histology and the clinicopathological characteristics of bone metastases.
    Lung Cancer. 2016;96:19-24.
    PubMed     Text format     Abstract available


  145. BENAVENT F, Capobianco CS, Garona J, Cirigliano SM, et al
    CIGB-300, an anti-CK2 peptide, inhibits angiogenesis, tumor cell invasion and metastasis in lung cancer models.
    Lung Cancer. 2016 Jun 1. pii: S0169-5002(16)30352.
    PubMed     Text format     Abstract available


    May 2016
  146. VAVALA T, Monica V, Lo Iacono M, Mele T, et al
    Precision medicine in age-specific non-small-cell-lung-cancer patients: Integrating biomolecular results into clinical practice-A new approach to improve personalized translational research.
    Lung Cancer. 2016 May 31. pii: S0169-5002(16)30348.
    PubMed     Text format     Abstract available


  147. TARTARONE A, Rossi E, Lerose R, Mambella G, et al
    Possible applications of circulating tumor cells in patients with non small cell lung cancer.
    Lung Cancer. 2016 May 31. pii: S0169-5002(16)30349.
    PubMed     Text format     Abstract available


  148. KOMIYA K, Sueoka-Aragane N, Sato A, Hisatomi T, et al
    Erratum to "Expression of Mina53, a novel c-Myc target gene, is a favorable prognostic marker in early stage lung cancer" [Lung Cancer 69/2 (2010) 232-238].
    Lung Cancer. 2016 May 27. pii: S0169-5002(16)30318.
    PubMed     Text format    


  149. AKCA H, Demiray A, Tokgun O, Yokota J, et al
    Erratum to "Invasiveness and anchorage independent growth ability augmented by PTEN inactivation through the PI3K/AKT/NFkB pathway in lung cancer cells" [Lung Cancer 73 (3) (2011) 302-309].
    Lung Cancer. 2016 May 24. pii: S0169-5002(16)30319.
    PubMed     Text format    


  150. DAUTZENBERG B, Garelik D
    Patients with lung cancer: Are electronic cigarettes harmful or useful?
    Lung Cancer. 2016 May 20. pii: S0169-5002(16)30323.
    PubMed     Text format     Abstract available


  151. SIWICKY MD, Petrik JJ, Moorehead RA
    Erratum to "The function of IGF-IR in NNK-mediated lung tumorigenesis" [Lung Cancer 71 (1) (2011) 11-18].
    Lung Cancer. 2016 May 5. pii: S0169-5002(16)30306.
    PubMed     Text format    


  152. SORBER L, Zwaenepoel K, Deschoolmeester V, Van Schil PE, et al
    Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.
    Lung Cancer. 2016 May 4. pii: S0169-5002(16)30312.
    PubMed     Text format     Abstract available


  153. O'DOWD EL, Luchtenborg M, Baldwin DR, McKeever TM, et al
    Predicting death from surgery for lung cancer: A comparison of two scoring systems in two European countries.
    Lung Cancer. 2016;95:88-93.
    PubMed     Text format     Abstract available


  154. VAVALA T, Follador A, Tiseo M, Galetta D, et al
    BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study.
    Lung Cancer. 2016;95:73-81.
    PubMed     Text format     Abstract available


  155. KANG HN, Kim SH, Yun MR, Kim HR, et al
    ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models.
    Lung Cancer. 2016;95:57-64.
    PubMed     Text format     Abstract available


  156. KUDJAWU YC, Chatellier G, Decool E, de Maria F, et al
    Timing in initiating lung cancer treatment after bronchoscopy in France: Study from medico-administrative database.
    Lung Cancer. 2016;95:44-50.
    PubMed     Text format     Abstract available


  157. DOESCH J, Debus D, Meyer C, Papadopoulos T, et al
    Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient.
    Lung Cancer. 2016;95:35-8.
    PubMed     Text format     Abstract available


  158. SCHROEDER MC, Tien YY, Wright K, Halfdanarson TR, et al
    Geographic variation in the use of adjuvant therapy among elderly patients with resected non-small cell lung cancer.
    Lung Cancer. 2016;95:28-34.
    PubMed     Text format     Abstract available


  159. BRENNER DR, Yannitsos DH, Farris MS, Johansson M, et al
    Leisure-time physical activity and lung cancer risk: A systematic review and meta-analysis.
    Lung Cancer. 2016;95:17-27.
    PubMed     Text format     Abstract available


  160. MOTH E, McLachlan SA, Veillard AS, Muljadi N, et al
    Patients' preferred and perceived roles in making decisions about adjuvant chemotherapy for non-small-cell lung cancer.
    Lung Cancer. 2016;95:8-14.
    PubMed     Text format     Abstract available


  161. BUTNOR KJ, Brownlee NA, Mahar A, Pavlisko EN, et al
    Diffuse malignant mesothelioma and synchronous lung cancer: A clinicopathological study of 18 cases.
    Lung Cancer. 2016;95:1-7.
    PubMed     Text format     Abstract available


  162. JU L, Han M, Zhao C, Li X, et al
    EGFR, KRAS and ROS1 variants coexist in a lung adenocarcinoma patient.
    Lung Cancer. 2016;95:94-7.
    PubMed     Text format     Abstract available


  163. METRO G, Ricciuti B, Chiari R, Baretti M, et al
    Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice.
    Lung Cancer. 2016;95:82-7.
    PubMed     Text format     Abstract available


  164. SIEGELE BJ, Shilo K, Chao BH, Carbone DP, et al
    Epidermal growth factor receptor (EGFR) mutations in small cell lung cancers: Two cases and a review of the literature.
    Lung Cancer. 2016;95:65-72.
    PubMed     Text format     Abstract available


  165. SAKAKURA N, Inaba Y, Yatabe Y, Mizuno T, et al
    Estimation of the pathological invasive size of pulmonary adenocarcinoma using high-resolution computed tomography of the chest: A consideration based on lung and mediastinal window settings.
    Lung Cancer. 2016;95:51-6.
    PubMed     Text format     Abstract available


  166. WANG Q, Zhao L, Yang X, Wei S, et al
    Antibody 1A4 with routine immunohistochemistry demonstrates high sensitivity for ALK rearrangement screening of Chinese lung adenocarcinoma patients: A single-center large-scale study.
    Lung Cancer. 2016;95:39-43.
    PubMed     Text format     Abstract available


  167. SASSIER M, Mennecier B, Gschwend A, Rein M, et al
    Successful treatment with ceritinib after crizotinib induced hepatitis.
    Lung Cancer. 2016;95:15-6.
    PubMed     Text format     Abstract available


    April 2016
  168. LUNG J, Lin YC, Hung MS, Jiang YY, et al
    A sensitive and high throughput TaqMan-based reverse transcription quantitative polymerase chain reaction assay efficiently discriminates ALK rearrangement from overexpression for lung cancer FFPE specimens.
    Lung Cancer. 2016;94:114-20.
    PubMed     Text format     Abstract available


  169. DICKHOFF C, Dahele M, Paul MA, van de Ven PM, et al
    Salvage surgery for locoregional recurrence or persistent tumor after high dose chemoradiotherapy for locally advanced non-small cell lung cancer.
    Lung Cancer. 2016;94:108-13.
    PubMed     Text format     Abstract available


  170. ROSELL A, Rodriguez N, Monso E, Taron M, et al
    Aberrant gene methylation and bronchial dysplasia in high risk lung cancer patients.
    Lung Cancer. 2016;94:102-7.
    PubMed     Text format     Abstract available


  171. VAN DER AALST CM, de Koning HJ
    Biochemical verification of the self-reported smoking status of screened male smokers of the Dutch-Belgian randomized controlled lung cancer screening trial.
    Lung Cancer. 2016;94:96-101.
    PubMed     Text format     Abstract available


  172. CAMERON SJ, Lewis KE, Beckmann M, Allison GG, et al
    The metabolomic detection of lung cancer biomarkers in sputum.
    Lung Cancer. 2016;94:88-95.
    PubMed     Text format     Abstract available


  173. DUDANI S, Leighl NB, Ho C, Pantarotto JR, et al
    Approach to the non-operative management of patients with stage II non-small cell lung cancer (NSCLC): A survey of Canadian medical and radiation oncologists.
    Lung Cancer. 2016;94:74-80.
    PubMed     Text format     Abstract available


  174. IMAMURA F, Uchida J, Kukita Y, Kumagai T, et al
    Monitoring of treatment responses and clonal evolution of tumor cells by circulating tumor DNA of heterogeneous mutant EGFR genes in lung cancer.
    Lung Cancer. 2016;94:68-73.
    PubMed     Text format     Abstract available


  175. LOUIE AV, Damhuis RA, Haasbeek CJ, Warner A, et al
    Treatment and survival of second primary early-stage lung cancer, following treatment of head and neck cancer in the Netherlands.
    Lung Cancer. 2016;94:54-60.
    PubMed     Text format     Abstract available


  176. CHEN LY, Molina-Vila MA, Ruan SY, Su KY, et al
    Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis.
    Lung Cancer. 2016;94:46-53.
    PubMed     Text format     Abstract available


  177. MENAMIN UC, Cardwell CR, Hughes CM, Murray LM, et al
    Metformin use and survival from lung cancer: A population-based cohort study.
    Lung Cancer. 2016;94:35-9.
    PubMed     Text format     Abstract available


  178. YIN Z, Cui Z, Ren Y, Xia L, et al
    Association between polymorphisms in pre-miRNA genes and risk of lung cancer in a Chinese non-smoking female population.
    Lung Cancer. 2016;94:15-21.
    PubMed     Text format     Abstract available


  179. SZYSZKO TA, Yip C, Szlosarek P, Goh V, et al
    The role of new PET tracers for lung cancer.
    Lung Cancer. 2016;94:7-14.
    PubMed     Text format     Abstract available


    March 2016
  180. PEROL M, Ciuleanu TE, Arrieta O, Prabhash K, et al
    Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy.
    Lung Cancer. 2016;93:95-103.
    PubMed     Text format     Abstract available


  181. TAVARES E CASTRO A, Clemente J, Carvalho L, Freitas S, et al
    Small-cell lung cancer in never-smokers: A case series.
    Lung Cancer. 2016;93:82-7.
    PubMed     Text format     Abstract available


  182. HIROSE T, Fujita K, Kusumoto S, Oki Y, et al
    Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer.
    Lung Cancer. 2016;93:69-76.
    PubMed     Text format     Abstract available


  183. TAN CS, Cho BC, Soo RA
    Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
    Lung Cancer. 2016;93:59-68.
    PubMed     Text format     Abstract available


  184. CHEN YM, Lai CH, Chang HC, Chao TY, et al
    The impact of clinical parameters on progression-free survival of non-small cell lung cancer patients harboring EGFR-mutations receiving first-line EGFR-tyrosine kinase inhibitors.
    Lung Cancer. 2016;93:47-54.
    PubMed     Text format     Abstract available


  185. HORIIKE A, Takeuchi K, Uenami T, Kawano Y, et al
    Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer.
    Lung Cancer. 2016;93:43-6.
    PubMed     Text format     Abstract available


  186. TONNIES S, Tonnies M, Kollmeier J, Bauer TT, et al
    Impact of preoperative 18F-FDG PET/CT on survival of resected mono-metastatic non-small cell lung cancer.
    Lung Cancer. 2016;93:28-34.
    PubMed     Text format     Abstract available


  187. VAN DEN BOOGAART VE, de Lussanet QG, Houben RM, de Ruysscher D, et al
    Inter-reader reproducibility of dynamic contrast-enhanced magnetic resonance imaging in patients with non-small cell lung cancer treated with bevacizumab and erlotinib.
    Lung Cancer. 2016;93:20-7.
    PubMed     Text format     Abstract available


  188. MENIAWY TM, Lake RA, McDonnell AM, Millward MJ, et al
    PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors.
    Lung Cancer. 2016;93:9-16.
    PubMed     Text format     Abstract available


  189. LIM SM, Cho BC, Kim SW, Kang SY, et al
    A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806).
    Lung Cancer. 2016;93:1-8.
    PubMed     Text format     Abstract available


  190. MENGOLI MC, Barbieri F, Bertolini F, Tiseo M, et al
    K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: Report of two cases and review of the literature.
    Lung Cancer. 2016;93:55-8.
    PubMed     Text format     Abstract available


  191. LI D, Zhang L, Zhou J, Chen H, et al
    Cigarette smoke extract exposure induces EGFR-TKI resistance in EGFR-mutated NSCLC via mediating Src activation and EMT.
    Lung Cancer. 2016;93:35-42.
    PubMed     Text format     Abstract available


  192. VAN GEEL RM, Hendrikx JJ, Vahl JE, van Leerdam ME, et al
    Crizotinib-induced fatal fulminant liver failure.
    Lung Cancer. 2016;93:17-9.
    PubMed     Text format     Abstract available


    February 2016
  193. KATO T, Wada H, Patel P, Hu HP, et al
    Overexpression of KIF23 predicts clinical outcome in primary lung cancer patients.
    Lung Cancer. 2016;92:53-61.
    PubMed     Text format     Abstract available


  194. TSURUGAI Y, Kozuka T, Ishizuka N, Oguchi M, et al
    Relationship between the consolidation to maximum tumor diameter ratio and outcomes following stereotactic body radiotherapy for stage I non-small-cell lung cancer.
    Lung Cancer. 2016;92:47-52.
    PubMed     Text format     Abstract available


  195. KRISHNASWAMY S, Mohammed AK, Amer OE, Tripathi G, et al
    Novel splicing variants of recepteur d'origine nantais (RON) tyrosine kinase involving exons 15-19 in lung cancer.
    Lung Cancer. 2016;92:41-6.
    PubMed     Text format     Abstract available


  196. SMIT E, Moro-Sibilot D, Carpeno Jde C, Lesniewski-Kmak K, et al
    Cisplatin and carboplatin-based chemotherapy in the first-line treatment of non-small cell lung cancer: Analysis from the European FRAME study.
    Lung Cancer. 2016;92:35-40.
    PubMed     Text format     Abstract available


  197. HAMES ML, Chen H, Iams W, Aston J, et al
    Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer.
    Lung Cancer. 2016;92:29-34.
    PubMed     Text format     Abstract available


  198. GUERRERO E, Ahmed M
    The role of stereotactic ablative radiotherapy (SBRT) in the management of oligometastatic non small cell lung cancer.
    Lung Cancer. 2016;92:22-8.
    PubMed     Text format     Abstract available


  199. MALOTTKI K, Popat S, Deeks JJ, Riley RD, et al
    Problems of variable biomarker evaluation in stratified medicine research-A case study of ERCC1 in non-small-cell lung cancer.
    Lung Cancer. 2016;92:1-7.
    PubMed     Text format     Abstract available


  200. KODITYAL S, Elvin JA, Squillace R, Agarwal N, et al
    A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib.
    Lung Cancer. 2016;92:19-21.
    PubMed     Text format     Abstract available


  201. CAUMONT C, Veillon R, Gros A, Laharanne E, et al
    Neuroendocrine phenotype as an acquired resistance mechanism in ALK-rearranged lung adenocarcinoma.
    Lung Cancer. 2016;92:15-8.
    PubMed     Text format     Abstract available


  202. SCHMIDT LH, Kuemmel A, Schliemann C, Schulze A, et al
    Blood group antigen A type 3 expression is a favorable prognostic factor in advanced NSCLC.
    Lung Cancer. 2016;92:8-14.
    PubMed     Text format     Abstract available


    January 2016
  203. KINOSHITA T, Fujii H, Hayashi Y, Kamiyama I, et al
    Prognostic significance of hypoxic PET using (18)F-FAZA and (62)Cu-ATSM in non-small-cell lung cancer.
    Lung Cancer. 2016;91:56-66.
    PubMed     Text format     Abstract available


  204. RIEBER J, Deeg A, Ullrich E, Foerster R, et al
    Outcome and prognostic factors of postoperative radiation therapy (PORT) after incomplete resection of non-small cell lung cancer (NSCLC).
    Lung Cancer. 2016;91:41-7.
    PubMed     Text format     Abstract available


  205. SUDA K, Murakami I, Sakai K, Tomizawa K, et al
    Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer.
    Lung Cancer. 2016;91:36-40.
    PubMed     Text format     Abstract available


  206. FIELD JK, Devaraj A, Duffy SW, Baldwin DR, et al
    CT screening for lung cancer: Is the evidence strong enough?
    Lung Cancer. 2016;91:29-35.
    PubMed     Text format     Abstract available


  207. TISSOT C, Couraud S, Tanguy R, Bringuier PP, et al
    Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.
    Lung Cancer. 2016;91:23-8.
    PubMed     Text format     Abstract available


  208. KIM G, An HJ, Lee MJ, Song JY, et al
    Hsa-miR-1246 and hsa-miR-1290 are associated with stemness and invasiveness of non-small cell lung cancer.
    Lung Cancer. 2016;91:15-22.
    PubMed     Text format     Abstract available


  209. DEBIEUVRE D, Oster JP, Riou R, Berruchon J, et al
    The new face of non-small-cell lung cancer in men: Results of two French prospective epidemiological studies conducted 10 years apart.
    Lung Cancer. 2016;91:1-6.
    PubMed     Text format     Abstract available


  210. CALLISTER ME, Baldwin DR
    How should pulmonary nodules be optimally investigated and managed?
    Lung Cancer. 2016;91:48-55.
    PubMed     Text format     Abstract available


  211. SARUWATARI K, Ikemura S, Sekihara K, Kuwata T, et al
    Aggressive tumor microenvironment of solid predominant lung adenocarcinoma subtype harboring with epidermal growth factor receptor mutations.
    Lung Cancer. 2016;91:7-14.
    PubMed     Text format     Abstract available


  212. BAAS P, van Meerbeeck J
    Money rules the world.
    Lung Cancer. 2016;91:77-8.
    PubMed     Text format    


  213. OU SH, Milliken JC, Azada MC, Miller VA, et al
    ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression.
    Lung Cancer. 2016;91:70-2.
    PubMed     Text format     Abstract available


    December 2015
  214. DAUTZENBERG B, Garelik D
    Patients with lung cancer: Are electronic cigarettes harmful, useful?
    Lung Cancer. 2015 Dec 24. pii: S0169-5002(15)30123.
    PubMed     Text format     Abstract available


  215. MORO-SIBILOT D, Smit E, de Castro Carpeno J, Lesniewski-Kmak K, et al
    Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: Analysis from the European FRAME study.
    Lung Cancer. 2015;90:427-32.
    PubMed     Text format     Abstract available


  216. KUSAGAYA H, Inui N, Karayama M, Fujisawa T, et al
    Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer.
    Lung Cancer. 2015;90:410-6.
    PubMed     Text format     Abstract available


  217. SCHMID-BINDERT G, Engel-Riedel W, Reck M, Schuette W, et al
    A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung Cancer.
    Lung Cancer. 2015;90:397-404.
    PubMed     Text format     Abstract available


  218. RICARDI U, Badellino S, Filippi AR
    Stereotactic body radiotherapy for early stage lung cancer: History and updated role.
    Lung Cancer. 2015;90:388-96.
    PubMed     Text format     Abstract available


  219. LI A, Niu FY, Han JF, Lou NN, et al
    Predictive and prognostic value of de novo MET expression in patients with advanced non-small-cell lung cancer.
    Lung Cancer. 2015;90:375-80.
    PubMed     Text format     Abstract available


    November 2015
  220. VERGNE F, Quere G, Andrieu-Key S, Descourt R, et al
    ALK-rearranged squamous cell lung carcinoma responding to crizotinib: A missing link in the field of non-small cell lung cancer?
    Lung Cancer. 2015 Nov 10. pii: S0169-5002(15)30106.
    PubMed     Text format     Abstract available


  221. VALLEE A, Audigier-Valette C, Herbreteau G, Merrien J, et al
    Rapid clearance of circulating tumor DNA during treatment with AZD9291 of a lung cancer patient presenting the resistance EGFR T790M mutation.
    Lung Cancer. 2015 Nov 7. pii: S0169-5002(15)30104.
    PubMed     Text format    


    October 2015
  222. LI BT, Lee A, O'Toole S, Cooper W, et al
    HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib.
    Lung Cancer. 2015 Oct 29. pii: S0169-5002(15)30093.
    PubMed     Text format     Abstract available


  223. HOWELL M, Chiramel J, Flaum N, Lewis A, et al
    Outcomes of octogenarian (>/=80 yo) patients with advanced non-small cell lung cancer (NSCLC): A single institution experience at the Christie Hospital.
    Lung Cancer. 2015 Oct 28. pii: S0169-5002(15)30094.
    PubMed     Text format    


  224. VON LAFFERT M, Stenzinger A, Hummel M, Weichert W, et al
    ALK-FISH borderline cases in non-small cell lung cancer: Implications for diagnostics and clinical decision making.
    Lung Cancer. 2015 Oct 23. pii: S0169-5002(15)30066.
    PubMed     Text format     Abstract available


  225. KAPTEIN AA, Kobayashi K, Matsuda A, Kubota K, et al
    We're in this together: Patients', caregivers' and health care providers' illness perceptions about non-small-cell lung cancer (NSCLC).
    Lung Cancer. 2015 Oct 19. pii: S0169-5002(15)30085.
    PubMed     Text format     Abstract available


  226. VERONESI G, Bottoni E, Finocchiaro G, Alloisio M, et al
    When is surgery indicated for small-cell lung cancer?
    Lung Cancer. 2015 Oct 17. pii: S0169-5002(15)30086.
    PubMed     Text format     Abstract available


  227. VAN DER LINDEN N, Bongers ML, Coupe VM, Smit EF, et al
    Costs of non-small cell lung cancer in the Netherlands.
    Lung Cancer. 2015 Oct 17. pii: S0169-5002(15)30084.
    PubMed     Text format     Abstract available


  228. EBERLE A, Jansen L, Castro F, Krilaviciute A, et al
    Lung cancer survival in Germany: A population-based analysis of 132,612 lung cancer patients.
    Lung Cancer. 2015 Oct 16. pii: S0169-5002(15)30076.
    PubMed     Text format     Abstract available


  229. MIKES RE, Jordan F, Hutarew G, Studnicka M, et al
    First line crizotinib in anaplastic lymphoma kinase (ALK) rearranged squamous cell lung cancer.
    Lung Cancer. 2015 Oct 16. pii: S0169-5002(15)30082.
    PubMed     Text format     Abstract available


  230. SHEN Q, Wang X, Yu B, Shi S, et al
    Comparing four different ALK antibodies with manual immunohistochemistry (IHC) to screen for ALK-rearranged non-small cell lung cancer (NSCLC).
    Lung Cancer. 2015 Oct 15. pii: S0169-5002(15)30071.
    PubMed     Text format     Abstract available


  231. KIM HJ, Jang SH, Ryu JS, Lee JE, et al
    The performance of a novel amino acid multivariate index for detecting lung cancer: A case control study in Korea.
    Lung Cancer. 2015 Oct 14. pii: S0169-5002(15)30075.
    PubMed     Text format     Abstract available


  232. GULACK BC, Yang CJ, Speicher PJ, Meza JM, et al
    The impact of tumor size on the association of the extent of lymph node resection and survival in clinical stage I non-small cell lung cancer.
    Lung Cancer. 2015 Oct 14. pii: S0169-5002(15)30080.
    PubMed     Text format     Abstract available


  233. YOKOUCHI H, Ishida T, Yamazaki S, Kikuchi H, et al
    Prognostic impact of clinical variables on surgically resected small-cell lung cancer: Results of a retrospective multicenter analysis (FIGHT002A and HOT1301A).
    Lung Cancer. 2015 Oct 14. pii: S0169-5002(15)30079.
    PubMed     Text format     Abstract available


  234. MEHTA HJ, Begnaud A, Penley AM, Wynne J, et al
    Treatment of isolated mediastinal and hilar recurrence of lung cancer with bronchoscopic endobronchial ultrasound guided intratumoral injection of chemotherapy with cisplatin.
    Lung Cancer. 2015 Oct 9. pii: S0169-5002(15)30078.
    PubMed     Text format     Abstract available


  235. GERBER DE, Boothman DA, Fattah FJ, Dong Y, et al
    Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer.
    Lung Cancer. 2015 Oct 9. pii: S0169-5002(15)30077.
    PubMed     Text format     Abstract available


  236. SCHMID S, Kubler M, Korcan Ayata C, Lazar Z, et al
    Altered purinergic signaling in the tumor associated immunologic microenvironment in metastasized non-small-cell lung cancer.
    Lung Cancer. 2015 Oct 9. pii: S0169-5002(15)30074.
    PubMed     Text format     Abstract available


  237. YOSHIDA T, Yoh K, Niho S, Umemura S, et al
    RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation.
    Lung Cancer. 2015 Oct 9. pii: S0169-5002(15)30069.
    PubMed     Text format     Abstract available


  238. TAN HS, Tan MH, Chow KY, Chay WY, et al
    Reproductive factors and lung cancer risk among women in the Singapore Breast Cancer Screening Project.
    Lung Cancer. 2015 Oct 8. pii: S0169-5002(15)30072.
    PubMed     Text format     Abstract available


    September 2015
  239. CANADAS I, Taus A, Villanueva X, Arpi O, et al
    Angiopoietin-2 is a negative prognostic marker in small cell lung cancer.
    Lung Cancer. 2015 Sep 26. pii: S0169-5002(15)30067.
    PubMed     Text format     Abstract available


  240. TALEBIAN YAZDI M, Egberts J, Schinkelshoek MS, Wolterbeek R, et al
    Endosonography for lung cancer staging: predictors for false-negative outcomes.
    Lung Cancer. 2015 Sep 25. pii: S0169-5002(15)30064.
    PubMed     Text format     Abstract available


  241. DU XL, Parikh RC, Lairson DR
    Racial and geographic disparities in the patterns of care and costs at the end of life for patients with lung cancer in 2007-2010 after the 2006 introduction of bevacizumab.
    Lung Cancer. 2015 Sep 21. pii: S0169-5002(15)30061.
    PubMed     Text format     Abstract available


  242. GROOTJANS W, Hermsen R, der Heijden EH, Schuurbiers-Siebers OC, et al
    The impact of respiratory gated positron emission tomography on clinical staging and management of patients with lung cancer.
    Lung Cancer. 2015 Sep 16. pii: S0169-5002(15)30060.
    PubMed     Text format     Abstract available


  243. JEREMIC B, Filipovic N, Milicic B, Milisavljevic S, et al
    Radiation therapy (RT) and chemotherapy (CHT) in stage II non-small cell lung cancer (NSCLC): Clinical entity neglected by radiation oncologists?
    Lung Cancer. 2015 Sep 16. pii: S0169-5002(15)30059.
    PubMed     Text format    


  244. MCKEEGAN EM, Ansell PJ, Davis G, Chan S, et al
    Plasma biomarker signature associated with improved survival in advanced non-small cell lung cancer patients on linifanib.
    Lung Cancer. 2015 Sep 15. pii: S0169-5002(15)30055.
    PubMed     Text format     Abstract available


  245. JIANG T, Ren S, Zhou C
    Role of circulating-tumor DNA analysis in non-small cell lung cancer.
    Lung Cancer. 2015 Sep 15. pii: S0169-5002(15)30057.
    PubMed     Text format     Abstract available


  246. MELLEMA WW, Masen-Poos L, Smit EF, Hendriks LE, et al
    Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer.
    Lung Cancer. 2015 Sep 15. pii: S0169-5002(15)30056.
    PubMed     Text format     Abstract available


  247. YAMAUCHI Y, Muley T, Safi S, Rieken S, et al
    The dynamic pattern of recurrence in curatively resected non-small cell lung cancer patients: Experiences at a single institution.
    Lung Cancer. 2015 Sep 15. pii: S0169-5002(15)30054.
    PubMed     Text format     Abstract available


  248. LEWIS KM, Bharadwaj U, Eckols TK, Kolosov M, et al
    Small-molecule targeting of signal transducer and activator of transcription (STAT) 3 to treat non-small cell lung cancer.
    Lung Cancer. 2015 Sep 15. pii: S0169-5002(15)30058.
    PubMed     Text format     Abstract available


  249. CHIARI R, Metro G, Iacono D, Bellezza G, et al
    Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis.
    Lung Cancer. 2015 Sep 14. pii: S0169-5002(15)30053.
    PubMed     Text format     Abstract available


  250. TU Q, Wu X, Le Rhun E, Blonski M, et al
    CellSearch technology applied to the detection and quantification of tumor cells in CSF of patients with lung cancer leptomeningeal metastasis.
    Lung Cancer. 2015 Sep 14. pii: S0169-5002(15)30052.
    PubMed     Text format     Abstract available


  251. SCHWARZKOPF L, Wacker M, Holle R, Leidl R, et al
    Cost-components of lung cancer care within the first three years after initial diagnosis in context of different treatment regimens.
    Lung Cancer. 2015 Sep 10. pii: S0169-5002(15)30049.
    PubMed     Text format     Abstract available


  252. WINTHER-LARSEN A, Nissen PH, Jakobsen KR, Demuth C, et al
    Genetic polymorphism in the epidermal growth factor receptor gene predicts outcome in advanced non-small cell lung cancer patients treated with erlotinib.
    Lung Cancer. 2015 Sep 8. pii: S0169-5002(15)30046.
    PubMed     Text format     Abstract available


  253. LEE SJ, Sun JM, Lee SH, Ahn JS, et al
    Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs.
    Lung Cancer. 2015 Sep 4. pii: S0169-5002(15)30044.
    PubMed     Text format     Abstract available


  254. JANSSENS A, Teugels L, Kohl S, Michielsen T, et al
    Integrating early palliative care (EPC) in the management of lung cancer: The role of the thoracic oncologist.
    Lung Cancer. 2015 Sep 1. pii: S0169-5002(15)30040.
    PubMed     Text format     Abstract available


    August 2015
  255. DURHAM AL, Adcock IM
    The relationship between COPD and lung cancer.
    Lung Cancer. 2015 Aug 29. pii: S0169-5002(15)30041.
    PubMed     Text format     Abstract available


  256. KOBAYASHI M, Nagashio R, Jiang SX, Saito K, et al
    Calnexin is a novel sero-diagnostic marker for lung cancer.
    Lung Cancer. 2015 Aug 28. pii: S0169-5002(15)30039.
    PubMed     Text format     Abstract available


  257. VAN IERSEL-VET MT, Thunnissen E, Spoelstra FO, Ylstra B, et al
    Diagnostic challenges in survivors of early stage lung cancer.
    Lung Cancer. 2015 Aug 24. pii: S0169-5002(15)30037.
    PubMed     Text format     Abstract available


  258. POWELL HA, Jones LL, Baldwin DR, Duffy JP, et al
    Patients' attitudes to risk in lung cancer surgery: A qualitative study.
    Lung Cancer. 2015 Aug 24. pii: S0169-5002(15)30038.
    PubMed     Text format     Abstract available


  259. ARRIETA O, Ramirez-Tirado LA, Baez-Saldana R, Pena-Curiel O, et al
    Different mutation profiles and clinical characteristics among Hispanic patients with non-small cell lung cancer could explain the "Hispanic paradox".
    Lung Cancer. 2015 Aug 22. pii: S0169-5002(15)30034.
    PubMed     Text format     Abstract available


  260. JIANG Y, Allen D, Kersemans V, Devery AM, et al
    Acute vascular response to cediranib treatment in human non-small-cell lung cancer xenografts with different tumour stromal architecture.
    Lung Cancer. 2015 Aug 20. pii: S0169-5002(15)30033.
    PubMed     Text format     Abstract available


  261. CHEN G, Sun X, Ren H, Wan X, et al
    The mortality patterns of lung cancer between 1990 and 2013 in Xuanwei, China.
    Lung Cancer. 2015 Aug 20. pii: S0169-5002(15)30030.
    PubMed     Text format     Abstract available


  262. KIM MS, Kim E, Heo JS, Bae DJ, et al
    Circulating IL-33 level is associated with the progression of lung cancer.
    Lung Cancer. 2015 Aug 20. pii: S0169-5002(15)30035.
    PubMed     Text format     Abstract available


  263. UMELO IA, Weverb O, Kronenberger P, Noor A, et al
    Combined inhibition of rho-associated protein kinase and EGFR suppresses the invasive phenotype in EGFR-dependent lung cancer cells.
    Lung Cancer. 2015 Aug 20. pii: S0169-5002(15)30032.
    PubMed     Text format     Abstract available


  264. BARNI S, Maiello E, Di Maio M, Ardizzoni A, et al
    Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatme
    Lung Cancer. 2015 Aug 19. pii: S0169-5002(15)30029.
    PubMed     Text format     Abstract available


  265. WANG X, Gu L, Zhang Y, Sargent DJ, et al
    Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups.
    Lung Cancer. 2015 Aug 18. pii: S0169-5002(15)30031.
    PubMed     Text format     Abstract available


  266. SUGIYAMA E, Umemura S, Nomura S, Kirita K, et al
    Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations.
    Lung Cancer. 2015 Aug 12. pii: S0169-5002(15)30028.
    PubMed     Text format     Abstract available


  267. RECK M, Mellemgaard A, von Pawel J, Gottfried M, et al
    Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel.
    Lung Cancer. 2015 Aug 12. pii: S0169-5002(15)30027.
    PubMed     Text format     Abstract available


  268. RUTTER CE, Park HS, Corso CD, Yeboa DN, et al
    Comparison of survival outcomes among standard radiotherapy regimens in limited-stage small cell lung cancer patients receiving concurrent chemoradiation.
    Lung Cancer. 2015 Aug 8. pii: S0169-5002(15)30026.
    PubMed     Text format     Abstract available


  269. DOBROVOLSKIENE NT, Cicenas S, Kazlauskaite N, Miseikyte-Kaubriene E, et al
    CD8CD57 T-cell population as an independent predictor of response to chemoradiation therapy in extensive-stage small cell lung cancer.
    Lung Cancer. 2015 Aug 4. pii: S0169-5002(15)30025.
    PubMed     Text format     Abstract available


  270. CHO EN, Kim EY, Jung JY, Kim A, et al
    BCL2-like 11 intron 2 deletion polymorphism is not associated with non-small cell lung cancer risk and prognosis.
    Lung Cancer. 2015 Aug 1. pii: S0169-5002(15)30023.
    PubMed     Text format     Abstract available


    July 2015
  271. TRACEY E, McCaughan B, Badgery-Parker T, Young J, et al
    Distance from accessible specialist care and other determinants of advanced or unknown stage at diagnosis of people with non-small cell lung cancer: A data linkage study.
    Lung Cancer. 2015 Jul 31. pii: S0169-5002(15)30024.
    PubMed     Text format     Abstract available


  272. KUEMMEL A, Simon P, Breitkreuz A, Rohlig J, et al
    Humoral immune responses of lung cancer patients against the Transmembrane Phosphatase with TEnsin homology (TPTE).
    Lung Cancer. 2015 Jul 30. pii: S0169-5002(15)30018.
    PubMed     Text format     Abstract available


  273. SHAVERDIAN N, Wang PC, Steinberg M, Lee P, et al
    The patient's perspective on stereotactic body radiation therapy (SBRT) vs. surgery for treatment of early stage non-small cell lung cancer (NSCLC).
    Lung Cancer. 2015 Jul 29. pii: S0169-5002(15)30015.
    PubMed     Text format     Abstract available


  274. GIATROMANOLAKI A, Kalamida D, Sivridis E, Karagounis IV, et al
    Increased expression of transcription factor EB (TFEB) is associated with autophagy, migratory phenotype and poor prognosis in non-small cell lung cancer.
    Lung Cancer. 2015 Jul 26. pii: S0169-5002(15)30014.
    PubMed     Text format     Abstract available


  275. NARITA Y, Matsushima Y, Shiroiwa T, Chiba K, et al
    Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer.
    Lung Cancer. 2015 Jul 26. pii: S0169-5002(15)30012.
    PubMed     Text format     Abstract available


  276. LI M, Yang D, Brock G, Knipp RJ, et al
    Breath carbonyl compounds as biomarkers of lung cancer.
    Lung Cancer. 2015 Jul 19. pii: S0169-5002(15)30011.
    PubMed     Text format     Abstract available


  277. AKHTAR-DANESH N, Finley C
    Temporal trends in the incidence and relative survival of non-small cell lung cancer in Canada: A population-based study.
    Lung Cancer. 2015 Jul 17. pii: S0169-5002(15)30010.
    PubMed     Text format     Abstract available


  278. WANG L, Jiang W, Zhan C, Shi Y, et al
    Lymph node metastasis in clinical stage IA peripheral lung cancer.
    Lung Cancer. 2015 Jul 11. pii: S0169-5002(15)30009.
    PubMed     Text format     Abstract available


  279. SJOBLOM B, Gronberg BH, Benth JS, Baracos VE, et al
    Low muscle mass is associated with chemotherapy-induced haematological toxicity in advanced non-small cell lung cancer.
    Lung Cancer. 2015 Jul 9. pii: S0169-5002(15)30007.
    PubMed     Text format     Abstract available


  280. LEE MS, Liu CY, Su L, Christiani DC, et al
    Polymorphisms in ERCC1 and ERCC2/XPD genes and carcinogen DNA adducts in human lung.
    Lung Cancer. 2015;89:8-12.
    PubMed     Text format     Abstract available


  281. DAVEY P, Ennis M, Aviv R
    Prophylactic cranial irradiation (PCI). Still a no-brainer?
    Lung Cancer. 2015;89:4-7.
    PubMed     Text format     Abstract available


  282. CHAUDHURI AA, Tang C, Binkley MS, Jin M, et al
    Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors.
    Lung Cancer. 2015;89:50-6.
    PubMed     Text format     Abstract available


  283. HSIEH MS, Lee YH, Chen JS, Lee JM, et al
    Mixed mucoepidermoid carcinoma and adenocarcinoma of the lung: Two cases with unusual histologic features.
    Lung Cancer. 2015;89:80-3.
    PubMed     Text format     Abstract available


  284. NAKAMURA S, Fukui T, Kawaguchi K, Fukumoto K, et al
    Does ground glass opacity-dominant feature have a prognostic significance even in clinical T2aN0M0 lung adenocarcinoma?
    Lung Cancer. 2015;89:38-42.
    PubMed     Text format     Abstract available


  285. AL-AMERI A, Malhotra P, Thygesen H, Plant PK, et al
    Risk of malignancy in pulmonary nodules: A validation study of four prediction models.
    Lung Cancer. 2015;89:27-30.
    PubMed     Text format     Abstract available


    June 2015
  286. SAMPATH S, Hall M, Schultheiss TE
    Definitive chemotherapy and radiotherapy in patients with stage II non-small cell lung cancer: A population-based outcomes study.
    Lung Cancer. 2015 Jun 29. pii: S0169-5002(15)30002.
    PubMed     Text format     Abstract available


  287. NISHIYAMA A, Katakami N, Yoshioka H, Iwasaku M, et al
    Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer.
    Lung Cancer. 2015 Jun 25. pii: S0169-5002(15)00302.
    PubMed     Text format     Abstract available


  288. GONG L, Xiong M, Huang Z, Miao L, et al
    Icotinib might be effective for the treatment of leptomeningeal carcinomatosis in non-small cell lung cancer with sensitive EGFR mutations.
    Lung Cancer. 2015 Jun 24. pii: S0169-5002(15)00286.
    PubMed     Text format     Abstract available


  289. LI Y, Zhao W, Zhao Z, Wu J, et al
    IL1B gene polymorphisms, age and the risk of non-small cell lung cancer in a Chinese population.
    Lung Cancer. 2015 Jun 23. pii: S0169-5002(15)00294.
    PubMed     Text format     Abstract available


  290. SWIATKOWSKA B, Szubert Z, Sobala W, Szeszenia-Dabrowska N, et al
    Predictors of lung cancer among former asbestos-exposed workers.
    Lung Cancer. 2015 Jun 22. pii: S0169-5002(15)00298.
    PubMed     Text format     Abstract available


  291. DAS M, Padda SK, Frymoyer A, Zhou L, et al
    Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction.
    Lung Cancer. 2015 Jun 22. pii: S0169-5002(15)00296.
    PubMed     Text format     Abstract available


  292. JIN Y, Sun PL, Park SY, Kim H, et al
    Frequent aerogenous spread with decreased E-cadherin expression of ROS1-rearranged lung cancer predicts poor disease-free survival.
    Lung Cancer. 2015 Jun 22. pii: S0169-5002(15)00297.
    PubMed     Text format     Abstract available


  293. SCHLUCKEBIER L, Garay OU, Zukin M, Ferreira CG, et al
    Carboplatin plus pemetrexed offers superior cost-effectiveness compared to pemetrexed in patients with advanced non-small cell lung cancer and performance status 2.
    Lung Cancer. 2015 Jun 22. pii: S0169-5002(15)00300.
    PubMed     Text format     Abstract available


  294. SHEN W, Yin R, Wang C, Zhu M, et al
    Polymorphisms in alternative splicing associated genes are associated with lung cancer risk in a Chinese population.
    Lung Cancer. 2015 Jun 22. pii: S0169-5002(15)00295.
    PubMed     Text format     Abstract available


  295. DIMITRAKOPOULOS FD, Antonacopoulou AG, Kottorou A, Marousi S, et al
    Variant of BCL3 gene is strongly associated with five-year survival of non-small-cell lung cancer patients.
    Lung Cancer. 2015 Jun 20. pii: S0169-5002(15)00291.
    PubMed     Text format     Abstract available


  296. ZHANG L, Zhang J, Ma Y, Chen J, et al
    Testicular orphan receptor 4 (TR4) is a marker for metastasis and poor prognosis in non-small cell lung cancer that drives the EMT phenotype.
    Lung Cancer. 2015 Jun 19. pii: S0169-5002(15)00292.
    PubMed     Text format     Abstract available


  297. LIU D, Zheng X, Chen J, Liu G, et al
    Induction chemotherapy with cetuximab, vinorelbine-cisplatin followed by thoracic radiotherapy and concurrent cetuximab, vinorelbine-cisplatin in patients with unresectable stage III non-small cell lung cancer.
    Lung Cancer. 2015 Jun 17. pii: S0169-5002(15)00289.
    PubMed     Text format     Abstract available


  298. ZHOU F, Jiang T, Ma W, Gao G, et al
    The impact of clinical characteristics on outcomes from maintenance therapy in non-small cell lung cancer: A systematic review with meta-analysis.
    Lung Cancer. 2015 Jun 17. pii: S0169-5002(15)00290.
    PubMed     Text format     Abstract available


  299. YOSHIMURA N, Kudoh S, Mitsuoka S, Yoshimoto N, et al
    Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation.
    Lung Cancer. 2015 Jun 15. pii: S0169-5002(15)00287.
    PubMed     Text format     Abstract available


  300. NISHINO K, Imamura F, Kumagai T, Katakami N, et al
    A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110).
    Lung Cancer. 2015 Jun 6. pii: S0169-5002(15)00283.
    PubMed     Text format     Abstract available


  301. KUIPER JL, Hendriks LE, van der Wekken AJ, de Langen AJ, et al
    Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis.
    Lung Cancer. 2015 Jun 6. pii: S0169-5002(15)00284.
    PubMed     Text format     Abstract available


  302. LIU D, Zhang L, Wu Y, Jiang J, et al
    Clinical pharmacokinetics, safety, and preliminary efficacy evaluation of icotinib in patients with advanced non-small cell lung cancer.
    Lung Cancer. 2015 Jun 6. pii: S0169-5002(15)00285.
    PubMed     Text format     Abstract available


  303. KANG N, Choi SY, Kim YK, Yoo IR, et al
    Silencing of miR-137 by aberrant promoter hypermethylation in surgically resected lung cancer.
    Lung Cancer. 2015 Jun 4. pii: S0169-5002(15)00247.
    PubMed     Text format     Abstract available


  304. KUMAR G, Woods B, Hess LM, Treat J, et al
    Cost-effectiveness of first-line induction and maintenance treatment sequences in non-squamous non-small cell lung cancer (NSCLC) in the U.S.
    Lung Cancer. 2015 Jun 3. pii: S0169-5002(15)00281.
    PubMed     Text format     Abstract available


    May 2015
  305. KOHUTEK ZA, Wu AJ, Zhang Z, Foster A, et al
    FDG-PET maximum standardized uptake value is prognostic for recurrence and survival after stereotactic body radiotherapy for non-small cell lung cancer.
    Lung Cancer. 2015 May 28. pii: S0169-5002(15)00275.
    PubMed     Text format     Abstract available


  306. MORO-SIBILOT D, Audigier-Valette C, Merle P, Quoix E, et al
    Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study).
    Lung Cancer. 2015 May 27. pii: S0169-5002(15)00272.
    PubMed     Text format     Abstract available


  307. LIN H, Huang YS, Yan HH, Yang XN, et al
    A family history of cancer and lung cancer risk in never-smokers: A clinic-based case-control study.
    Lung Cancer. 2015 May 27. pii: S0169-5002(15)00273.
    PubMed     Text format     Abstract available


  308. CAO C, Chandrakumar D, Gupta S, Yan TD, et al
    Could less be more?-A systematic review and meta-analysis of sublobar resections versus lobectomy for non-small cell lung cancer according to patient selection.
    Lung Cancer. 2015 May 19. pii: S0169-5002(15)00246.
    PubMed     Text format     Abstract available


  309. ADAM V, Dooms C, Vansteenkiste J
    Lung cancer at the intensive care unit: The era of targeted therapy.
    Lung Cancer. 2015 May 18. pii: S0169-5002(15)00245.
    PubMed     Text format     Abstract available


  310. VIGOUROUX C, Casse JM, Battaglia-Hsu SF, Brochin L, et al
    Methyl(R217)HuR and MCM6 are inversely correlated and are prognostic markers in non small cell lung carcinoma.
    Lung Cancer. 2015 May 16. pii: S0169-5002(15)00244.
    PubMed     Text format     Abstract available


  311. SASSIER M, Dugue AE, Clarisse B, Lesueur P, et al
    Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed) discontinuation for toxicity to advanced non-small cell lung cancer in real world setting.
    Lung Cancer. 2015 May 15. pii: S0169-5002(15)00241.
    PubMed     Text format     Abstract available


  312. BALDWIN DR
    Prediction of risk of lung cancer in populations and in pulmonary nodules: Significant progress to drive changes in paradigms.
    Lung Cancer. 2015 May 14. pii: S0169-5002(15)00240.
    PubMed     Text format     Abstract available


  313. CORSO CD, Park HS, Kim AW, Yu JB, et al
    Racial disparities in the use of SBRT for treating early-stage lung cancer.
    Lung Cancer. 2015 May 12. pii: S0169-5002(15)00238.
    PubMed     Text format     Abstract available


  314. LAL R, Hillerdal GN, Shah RN, Crosse B, et al
    Feasibility of home delivery of pemetrexed in patients with advanced non-squamous non-small cell lung cancer.
    Lung Cancer. 2015 May 12. pii: S0169-5002(15)00239.
    PubMed     Text format     Abstract available


  315. KUCHUK M, Kuchuk I, Sabri E, Hutton B, et al
    The incidence and clinical impact of bone metastases in non-small cell lung cancer.
    Lung Cancer. 2015 May 11. pii: S0169-5002(15)00206.
    PubMed     Text format     Abstract available


  316. OWONIKOKO TK, Dahlberg SE, Khan SA, Gerber DE, et al
    A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511).
    Lung Cancer. 2015 May 8. pii: S0169-5002(15)00233.
    PubMed     Text format     Abstract available


  317. WESTOVER KD, Iyengar P, Sharma AN, Timmerman R, et al
    SABR for aggressive local therapy of metastatic cancer: A new paradigm for metastatic non-small cell lung cancer.
    Lung Cancer. 2015 May 8. pii: S0169-5002(15)00208.
    PubMed     Text format     Abstract available


  318. SANZ RUBIALES A, Del Valle Rivero ML, Fiorini Talavera AB, Fernandez Gonzalez M, et al
    Platinum derivatives alone, a reasonable option to treat locally advanced non-small cell lung cancer with chemo-radiotherapy.
    Lung Cancer. 2015 May 6. pii: S0169-5002(15)00212.
    PubMed     Text format    


  319. INOUE A, Sugawara S, Maemondo M, Mori Y, et al
    Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702.
    Lung Cancer. 2015 May 4. pii: S0169-5002(15)00211.
    PubMed     Text format     Abstract available


  320. TSAI TH, Wu SG, Hsieh MS, Yu CJ, et al
    Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.
    Lung Cancer. 2015;88:208-14.
    PubMed     Text format     Abstract available


  321. SORENSEN SF, Carus A, Meldgaard P
    Intravenous or oral administration of vinorelbine in adjuvant chemotherapy with cisplatin and vinorelbine for resected NSCLC.
    Lung Cancer. 2015;88:167-73.
    PubMed     Text format     Abstract available


  322. MAO K, Liu F, Liu X, Khuri FR, et al
    Re-expression of LKB1 in LKB1-mutant EKVX cells leads to resistance to paclitaxel through the up-regulation of MDR1 expression.
    Lung Cancer. 2015;88:131-8.
    PubMed     Text format     Abstract available


  323. WANG P, Lu S, Mao H, Bai Y, et al
    Identification of biomarkers for the detection of early stage lung adenocarcinoma by microarray profiling of long noncoding RNAs.
    Lung Cancer. 2015;88:147-53.
    PubMed     Text format     Abstract available


  324. WU KL, Tsai MJ, Yang CJ, Chang WA, et al
    Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib.
    Lung Cancer. 2015;88:187-94.
    PubMed     Text format     Abstract available


  325. OU SH, Greenbowe J, Khan ZU, Azada MC, et al
    I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.
    Lung Cancer. 2015;88:231-4.
    PubMed     Text format     Abstract available


  326. FUKUHARA T, Maemondo M, Inoue A, Kobayashi K, et al
    Factors associated with a poor response to gefitinib in the NEJ002 study: smoking and the L858R mutation.
    Lung Cancer. 2015;88:181-6.
    PubMed     Text format     Abstract available


    April 2015
  327. SUBBIAH V, Berry J, Roxas M, Guha-Thakurta N, et al
    Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.
    Lung Cancer. 2015 Apr 22. pii: S0169-5002(15)00203.
    PubMed     Text format     Abstract available


  328. VINCENTEN JP, Smit EF, Grunberg K, Postmus PE, et al
    Is the current diagnostic algorithm reliable for selecting cases for EGFR- and KRAS-mutation analysis in lung cancer?
    Lung Cancer. 2015 Apr 20. pii: S0169-5002(15)00204.
    PubMed     Text format     Abstract available


  329. REIS H, Herold T, Ting S, Worm K, et al
    HER2 expression and markers of phosphoinositide-3-kinase pathway activation define a favorable subgroup of metastatic pulmonary adenocarcinomas.
    Lung Cancer. 2015;88:34-41.
    PubMed     Text format     Abstract available


  330. LE X, Desai NV, Majid A, Karp RS, et al
    De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors.
    Lung Cancer. 2015;88:70-3.
    PubMed     Text format     Abstract available


  331. RANGACHARI D, Yamaguchi N, VanderLaan PA, Folch E, et al
    Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers.
    Lung Cancer. 2015;88:108-11.
    PubMed     Text format     Abstract available


  332. WIECKOWSKI S, Hemmerle T, Prince SS, Schlienger BD, et al
    Therapeutic efficacy of the F8-IL2 immunocytokine in a metastatic mouse model of lung adenocarcinoma.
    Lung Cancer. 2015;88:9-15.
    PubMed     Text format     Abstract available


  333. SELLA T, Botser D, Navon R, Biran H, et al
    Preferences for disclosure of disease related information among thoracic cancer patients.
    Lung Cancer. 2015;88:100-3.
    PubMed     Text format     Abstract available


  334. DE GREVE J, Moran T, Graas MP, Galdermans D, et al
    Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma.
    Lung Cancer. 2015;88:63-9.
    PubMed     Text format     Abstract available


  335. KIM MY, Koh J, Kim S, Go H, et al
    Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
    Lung Cancer. 2015;88:24-33.
    PubMed     Text format     Abstract available


  336. GRIFFIOEN GH, Louie AV, de Bree R, Smit EF, et al
    Second primary lung cancers following a diagnosis of primary head and neck cancer.
    Lung Cancer. 2015;88:94-9.
    PubMed     Text format     Abstract available


    March 2015
  337. WILLIAMS M, Liu ZW, Hunter A, Macbeth F, et al
    An updated systematic review of lung chemo-radiotherapy using a new evidence aggregation method.
    Lung Cancer. 2015;87:290-5.
    PubMed     Text format     Abstract available


  338. PELOSI G, Barbareschi M, Cavazza A, Graziano P, et al
    Large cell carcinoma of the lung: a tumor in search of an author. A clinically oriented critical reappraisal.
    Lung Cancer. 2015;87:226-31.
    PubMed     Text format     Abstract available


  339. JIANG L, He J, Shi X, Shen J, et al
    Prognosis of synchronous and metachronous multiple primary lung cancers: systematic review and meta-analysis.
    Lung Cancer. 2015;87:303-10.
    PubMed     Text format     Abstract available


  340. ROBESOVA B, Bajerova M, Hausnerova J, Skrickova J, et al
    Identification of atypical ATRNL1 insertion to EML4-ALK fusion gene in NSCLC.
    Lung Cancer. 2015;87:318-20.
    PubMed     Text format     Abstract available


  341. TONG KM, Laskin J, Ho C
    Maintenance chemotherapy in advanced NSCLC: a population-based assessment of eligibility.
    Lung Cancer. 2015;87:296-302.
    PubMed     Text format     Abstract available


  342. MEDJBER K, Freidja ML, Grelet S, Lorenzato M, et al
    Role of nicotinic acetylcholine receptors in cell proliferation and tumour invasion in broncho-pulmonary carcinomas.
    Lung Cancer. 2015;87:258-64.
    PubMed     Text format     Abstract available


  343. YANG Y, Yang Y, Zhou X, Song X, et al
    EGFR L858R mutation is associated with lung adenocarcinoma patients with dominant ground-glass opacity.
    Lung Cancer. 2015;87:272-7.
    PubMed     Text format     Abstract available


    February 2015
  344. KOCHER F, Hilbe W, Seeber A, Pircher A, et al
    Longitudinal analysis of 2293 NSCLC patients: a comprehensive study from the TYROL registry.
    Lung Cancer. 2015;87:193-200.
    PubMed     Text format     Abstract available


    January 2015

  345. Abstracts of the 13th Annual British Thoracic Oncology Group Conference 2015, 28-30 January 2015, Dublin, Ireland.
    Lung Cancer. 2015;87 Suppl 1:S1-78.
    PubMed     Text format    


  346. NAKAMURA H, Saji H, Shinmyo T, Tagaya R, et al
    Close association of IASLC/ATS/ERS lung adenocarcinoma subtypes with glucose-uptake in positron emission tomography.
    Lung Cancer. 2015;87:28-33.
    PubMed     Text format     Abstract available


  347. MIYAHARA S, Hamasaki M, Hamatake D, Yamashita S, et al
    Clinicopathological analysis of pleomorphic carcinoma of the lung: diffuse ZEB1 expression predicts poor survival.
    Lung Cancer. 2015;87:39-44.
    PubMed     Text format     Abstract available


  348. SUZUKI M, Shiraishi K, Yoshida A, Shimada Y, et al
    HER2 gene mutations in non-small cell lung carcinomas: concurrence with Her2 gene amplification and Her2 protein expression and phosphorylation.
    Lung Cancer. 2015;87:14-22.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: